Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities

Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?

(2022) Serena Silvestro et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease

(2022) Melanie D. Whittington et al.   NEUROLOGY

Regulatory decisions diverge over aducanumab for Alzheimer’s disease

(2022) Mark P Lythgoe et al.   BMJ-British Medical Journal

Evaluation of Aducanumab for Alzheimer Disease

(2021) G. Caleb Alexander et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering

(2021) Jeffrey Cummings et al.   Alzheimers Research & Therapy

FDA Approval of Aducanumab Divided the Community but Also Connected and United It

(2021) Jacob M. Hooker   ACS Chemical Neuroscience

Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease

(2021) Konstantinos I. Avgerinos et al.   AGEING RESEARCH REVIEWS

Alzheimer's and Aducanumab: Unjust Profits and False Hopes

(2021) Leonard M. Fleck   HASTINGS CENTER REPORT

Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered

(2021) Rita Rubin   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer’s Disease

(2021) Sanchari Mukhopadhyay et al.   JOURNAL OF ALZHEIMERS DISEASE

Landmark Alzheimer’s drug approval confounds research community

(2021) Asher Mullard   NATURE

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

(2021) Stephen Salloway et al.   NATURE MEDICINE

Revisiting FDA Approval of Aducanumab

(2021) G. Caleb Alexander et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aducanumab for Alzheimer’s disease: A regulatory perspective

(2021) Robert Nisticò et al.   PHARMACOLOGICAL RESEARCH

Three FDA advisory panel members resign over approval of Alzheimer’s drug

(2021) Elisabeth Mahase   BMJ-British Medical Journal

Aducanumab for Alzheimer’s disease?

(2021) Sebastian Walsh et al.   BMJ-British Medical Journal

Fulfilling the Mandate of the US Food and Drug Administration’s Accelerated Approval Pathway

(2021) Bishal Gyawali et al.   JAMA Internal Medicine

How the US Food and Drug Administration’s approval of aducanumab for Alzheimer's disease has implication for oncology and beyond

(2021) Mark P. Lythgoe et al.   EUROPEAN JOURNAL OF CANCER

Aducanumab: European agency rejects Alzheimer’s drug over efficacy and safety concerns

(2021) Elisabeth Mahase   BMJ-British Medical Journal

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease

(2021) Antoine Leuzy et al.   JAMA Neurology

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease

(2021) Stephen Salloway et al.   JAMA Neurology

Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET

(2020) Renaud La Joie et al.   Science Translational Medicine

Oligomerization and Conformational Change Turn Monomeric β-Amyloid and Tau Proteins Toxic: Their Role in Alzheimer’s Pathogenesis

(2020) Botond Penke et al.   MOLECULES

Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer’s disease or should they be looking elsewhere?

(2020) Bruno Pietro Imbimbo et al.   Expert Opinion on Drug Discovery

Unblinded by the light: amyloid‐related imaging abnormalities in Alzheimer’s clinical trials

(2020) A. Gleason et al.   EUROPEAN JOURNAL OF NEUROLOGY

Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies

(2020) Sara Linse et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

The neuropathological diagnosis of Alzheimer’s disease

(2019) Michael A. DeTure et al.   Molecular Neurodegeneration

Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric Aβ and Tau Species

(2019) Xu-Qiao Chen et al.   Frontiers in Neuroscience

Alzheimer Disease: An Update on Pathobiology and Treatment Strategies

(2019) Justin M. Long et al.   CELL

Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways

(2019) Steven M. Greenberg et al.   Nature Reviews Neurology

The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade

(2018) Erika N. Cline et al.   JOURNAL OF ALZHEIMERS DISEASE

Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β

(2018) Joseph W. Arndt et al.   Scientific Reports

Alzheimer's disease

(2017) C. A. Lane et al.   EUROPEAN JOURNAL OF NEUROLOGY

The amyloid hypothesis of Alzheimer's disease at 25 years

(2016) Dennis J Selkoe et al.   EMBO Molecular Medicine

Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

(2016) Ross Penninkilampi et al.   Journal of Neuroimmune Pharmacology

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia